Clinical trials: Gastrointestinal and Digestive Disorder
Pancreatic Cancer
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
Metastatic Pancreatic Cancer Disease is one of the most aggressive and deadliest forms of cancer with very poor survival. This study will evaluate adverse events and change in disease activity in participants 18 to 75 years of…
- Trial name
- NCT04807972
- Testing
- ABBV-927, Budiglimab, modified FOLFIRINOX
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Gastrointestinal Stromal Tumors
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
This is a multicenter, post-marketing, clinical study evaluating the safety and efficacy of postoperative adjuvant therapy with Imatinib Mesylate in high-risk patients after curative resection of newly diagnosed GIST.Patients…
- Trial name
- NCT00171977
- Testing
- Imatinib Mesylate
- Where
- Japan
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Gastroesophageal Reflux Disease (GERD)
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
This study is a phase III, multi-centre, randomized, double-blind study to assess the safety and tolerability of once daily treatment with esomeprazole 20 or 40 mg in pediatric and adolescent patients 12 to 17 years of age…
- Trial name
- NCT00241501
- Testing
- Esomeprazole (Nexium)
- Where
- 40 sites in United States, Canada and 2 more
- Volunteers
- 140 people
- Sponsor
- AstraZeneca
Pancreatic Disease
A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers
The following are the study hypothesis: Secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples being predominantly of exocrine pancreas origin when…
- Trial name
- CRC2006-05 (NCT01087801)
- Testing
- ChiRhoStim
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- ChiRhoClin, Inc.
Hepatitis C, Chronic
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin).
- Trial name
- NCT01429792
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- 26 sites in Israel
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Pancreatitis, Chronic, Stricture; Bile Duct
GORE® VIABIL® Biliary Endoprosthesis in the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis
This study will evaluate the safety and effectiveness of the GORE® VIABIL® Biliary Endoprosthesis in the treatment of benign biliary strictures secondary to Chronic Pancreatitis (CP).
- Trial name
- VIABILITY (NCT05820009)
- Testing
- GORE® VIABIL® Biliary Endoprosthesis, GORE® VIABIL® Short Wire Biliary Endoprosthesis
- Where
- 2 sites in United States
- Volunteers
- 133 people
- Sponsor
- W.L.Gore & Associates
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
GIST
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
The purpose of this study is to evaluate the efficacy and safety of ponatinib in participants with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure of prior tyrosine kinase inhibitor (TKI)…
- Trial name
- GIST (NCT01874665)
- Testing
- Ponatinib
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ariad Pharmaceuticals
Non-Alcoholic Steatohepatitis (NASH), Type2 Diabetes Mellitus
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
This is an open, pilot study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM or pre-diabetes.
- Trial name
- NCT02653300
- Testing
- Oral Insulin
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Oramed, Ltd.
Esophageal Carcinoma, Gastroesophageal Junction Carcinoma
A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
- Trial name
- PROSPECT-ESO (NCT05780736)
- Where
- 24 sites in United States, Germany
- Volunteers
- 33 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
To compare the polyp and adenoma detection rate of MOVIPREP versus an oral Sodium Picosulfate/Magnesium Citrate solution.
- Trial name
- NCT01689792
- Testing
- MOVIPREP, CitraFleet
- Where
- Germany
- Volunteers
- 398 people
- Sponsor
- Norgine
Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
- Trial name
- NCT04956640
- Testing
- LY3537982, Pembrolizumab, Cetuximab
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 540 people
- Sponsor
- Eli Lilly and Company
Cancer, Breast, Cancer, Lung
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid…
- Conditions
- Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus
- Trial name
- NCT05830097
- Testing
- CBP-1019
- Where
- 5 sites in United States, China
- Volunteers
- 260 people
- Sponsor
- Coherent Biopharma (Hefei) Co., Ltd.
Ulcerative Colitis
A Study to Learn About the Safety, Effects and Pharmacokinetics of Study Medication (PF-07054894) for the Treatment of Ulcerative Colitis
This is a study to learn if the experimental medicine (called PF-07054894) is safe, effective, and how it is processed in adult people with ulcers in the colon.
- Trial name
- NCT05549323
- Testing
- PF-07054894
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Pfizer
Growth, Tolerance
Human Milk Oligosaccharides (HMOs) Post-market Study on Infants (NEHMO)
Human milk oligosaccharides (HMOs) represent the third largest solid component of breast milk. Technology advancements made it possible to supplement infant formulas with HMOs (2'FL, LNnT).
- Conditions
- Growth, Tolerance, Adverse Event, Disorder of Intestine
- Trial name
- NeHMO DACH (NCT05150288)
- Testing
- HMO-supplemented infant formula
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Colorectal Cancer
Tumour Registry Colorectal Cancer
To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.
- Trial name
- TKK (NCT00910819)
- Where
- Germany
- Volunteers
- 7,000 people
- Sponsor
- iOMEDICO AG
Chronic Hepatitis B
A Study to Evaluate the Mass Balance Absorption and AME of VBR
This Phase 1 Study will determine the mass balance recovery, absorption, metabolism, and excretion of [14C] Vebicorvir in healthy male subjects
- Trial name
- NCT04637139
- Testing
- Vebicorvir (VBR)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Assembly Biosciences
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Hepatitis C, Chronic, Hepatitis C
Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)
In patients with chronic hepatitis C, the ultimate treatment goal is the improvement of liver histology and inhibition of progression to liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT00787371
- Testing
- PegIntron (peginterferon alfa-2b)
- Volunteers
- 69 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.